Screener
Immix Biopharma, Inc. IMMX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Short-term investments | 11,328,999 | 6,480,860 |
| Prepaid expenses and other current assets | 1,695,649 | 828,329 |
| Total current assets | 92,274,811 | 101,237,755 |
| Other assets | 20,418 | 20,418 |
| Deferred offering costs | 164,723 | 93,630 |
| Right-of-use asset, net | 927,728 | 966,917 |
| Property and equipment, net | 2,428,377 | 2,521,621 |
| Total assets | $95,816,057 | $104,840,341 |
Document
FAQ
- What is Immix Biopharma, Inc.'s deferred tax assets and other non-current assets?
- Immix Biopharma, Inc. (IMMX) reported deferred tax assets and other non-current assets of $20.42K in Q1 2026.
- How has Immix Biopharma, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Immix Biopharma, Inc.'s deferred tax assets and other non-current assets decreased by 0.0% year-over-year, from $20.42K to $20.42K.
- What is the long-term trend for Immix Biopharma, Inc.'s deferred tax assets and other non-current assets?
- Over 2 years (2022 to 2025), Immix Biopharma, Inc.'s deferred tax assets and other non-current assets has grown at a 74.3% compound annual growth rate (CAGR), from $6.72K to $20.42K.
Ask your AI about Immix Biopharma, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude